Is het Sysmex dividend veilig?
Sysmex verhoogt het dividend al 3 jaar.
Binnen de laatste 10 jaar heeft Sysmex deze met jaarlijks -1,133 % verlaagd verhoogd.
Op 5-jaarsbasis is de uitkering met daalde toegenomen met -16,629 %.
De analisten verwachten voor het lopende boekjaar een Dividendverlaging van -0,657%.
Sysmex Aktienanalyse
Wat doet Sysmex?
Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide.
History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972.
Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology.
Divisions: Sysmex Corp is divided into three main business divisions:
1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer.
2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory.
3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue.
Products: Sysmex offers a variety of products, including:
- Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets.
- Hemostasis systems for analyzing blood coagulation.
- Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer.
- Urinalysis systems for analyzing urine samples for chemical and microscopic parameters.
- Immunology analysis devices for determining specific proteins and antibodies in the blood.
- Clinical chemistry analysis devices for analyzing chemical parameters in blood samples.
- Software and IT solutions for optimizing laboratory processes and management.
- Cell analysis and imaging systems for investigating cell morphology and functions.
- Devices for harvesting mesenchymal stem cells from adipose tissue.
In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex is een van de populairste bedrijven op Eulerpool.com.Aandelen spaarplannen bieden een aantrekkelijke mogelijkheid voor beleggers om op de lange termijn vermogen op te bouwen. Een van de belangrijkste voordelen is het zogenaamde cost-average-effect: door regelmatig een vast bedrag in aandelen of aandelenfondsen te investeren, koopt men automatisch meer aandelen wanneer de prijzen laag zijn, en minder wanneer ze hoog zijn. Dit kan leiden tot een voordeligere gemiddelde prijs per aandeel over de tijd. Bovendien maken aandelen spaarplannen het ook voor kleine beleggers mogelijk om toegang te krijgen tot dure aandelen, aangezien ze al met kleine bedragen kunnen deelnemen. De regelmatige investering bevordert ook een gedisciplineerde beleggingsstrategie en helpt emotionele beslissingen, zoals impulsief kopen of verkopen, te voorkomen. Daarnaast profiteren beleggers van de potentiële waardestijging van de aandelen en van dividenduitkeringen die herinvesteerd kunnen worden, wat het effect van samengestelde interest versterkt en daarmee de groei van het geïnvesteerde kapitaal.